TLGT Teligent Inc.

Teligent, Inc. Announces the Appointment of John Celentano as Chairman of the Board

Teligent, Inc. Announces the Appointment of John Celentano as Chairman of the Board

BUENA, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, is pleased to announce that John Celentano, a current independent director of Teligent, has been appointed Chairman of Teligent's Board of Directors, replacing James C. Gale who opted to not stand for reelection to Teligent’s board of directors in order to devote more time to other business interests.

Mr. Celentano joined Teligent as a director in March 2015.  He will also continue to serve as a member of Teligent's Compensation and Audit Committees.

Previously, Mr. Celentano held key senior leadership positions with Bristol-Myers Squibb Company including: President, Bristol-Myers Squibb Healthcare Group (Mead Johnson Nutrition, ConvaTec, and Medical Imaging); Regional President roles in Emerging Markets/Asia Pacific, Latin America/Canada, and UK/Northern Europe; Senior Vice President of Human Resources, Public Affairs and Philanthropy; and Senior Vice President of Strategy and Productivity.

While at Bristol-Myers, Mr. Celentano was an active participant in the development of their biopharma strategy and led major initiatives on productivity transformation, streamlining operations to support the company’s growth opportunities. Mr. Celentano currently works as an independent senior advisor and serves on the Board of privately held YourEncore Inc. He holds a B.A. from the University of Delaware and an MBA from Drexel University.

"We are excited to leverage John’s broad, extensive experience in the pharmaceutical industry and proven boardroom leadership in the role of Chairman of Teligent’s Board of Directors," said Timothy B. Sawyer, Teligent's President and CEO.  "We look forward to working closely with John as our new Chairman and the Board joins me in thanking Jim Gale for his service and wishing him well as he focuses on his private endeavors."

About Teligent, Inc.

Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website .

Contact:

Damian Finio

Teligent, Inc.

856-336-9117

EN
20/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teligent Inc.

 PRESS RELEASE

Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provi...

Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update –Update on FDA Inspection of Buena Facility–Assessing New Growth Opportunities in Injectables–Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time –Dial in: (877) 407-0792 US Toll Free Number  (201) 689-8263 International Number  Confirmation Number: 13721972 BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a busi...

 PRESS RELEASE

Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financi...

Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021 BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update. Conference Call InformationDate: Monday, August 16, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0792 International: 201-6...

 PRESS RELEASE

Teligent, Inc. Announces Adjournment of Annual Meeting of Stockholders

Teligent, Inc. Announces Adjournment of Annual Meeting of Stockholders Scheduled to Reconvene on July 21, 2021Company Urgently Encourages Stockholders to Vote BUENA, N.J., June 30, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021 and adjourned to June 30, 2021, was convened and adjourned without any business being conducted due to the fact that there were not sufficient votes to approve all of the proposals presented at t...

 PRESS RELEASE

Teligent, Inc. Announces Adjournment of Annual Meeting of Stockholders

Teligent, Inc. Announces Adjournment of Annual Meeting of Stockholders Scheduled to Reconvene on June 30, 2021Company Urgently Encourages Stockholders to Vote BUENA, N.J., June 18, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021, was convened and adjourned without any business being conducted due to the fact that there were not sufficient votes to approve all of the proposals presented at the Annual Meeting. The Company ...

 PRESS RELEASE

Teligent, Inc. Announces First Quarter 2021 Earnings Report and Provid...

Teligent, Inc. Announces First Quarter 2021 Earnings Report and Provides Business Update –Continued Remediation Progress Being Made–Reiterating Prior Guidance of Informing FDA on Inspection Readiness During 3Q2021–Conference Call to Be Held on May 25, 2021 at 4:30 pm Eastern Standard Time –Dial in: (800) 708-4540 US Toll Free Number  (847) 619-6397 US Number  Confirmation Number: 50161966 BUENA, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the first quarter of 2021 and pr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch